Cambridge, United States
Ymir Genomics is a biotechnology startup founded in 2011 with a focus on discovering biomarkers for diagnostics and therapeutics. The company has developed a proprietary protocol for isolating exosomal RNA and proteins from biofluids such as blood, saliva, and urine, which is two to 10 times more efficient than current commercial kits. This not only saves time and cost, but also enhances the potential for commercialization. Ymir is optimizing this protocol for commercial use and concurrently utilizing it, along with a novel bioinformatics protocol, to identify urine biomarkers for prostate and bladder cancer.
With its dedication to finding easily assayable circulating RNA biomarkers, Ymir Genomics aims to make significant advancements in the health and wellness industry. However, specific details regarding the headquarters, last investment, and investors are currently not available. As a promising player in the biotechnology sector, Ymir Genomics presents an exciting potential for investment, especially with its innovative approach to developing diagnostic and therapeutic solutions. Investors should closely monitor the commercialization progress and the outcomes of the company's efforts in biomarker discovery for cancer.
